Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus

Coronary Artery Disease

Volumn 26, Issue 5, 2015, Pages 396-401

  Ozturk, Derya ^a   Celik, Omer ^a   Satilmis, Seckin ^b   Aslan, Serkan ^a   Erturk, Mehmet ^a   Cakmak, Huseyin Altug ^c   Kalkan, Ali Kemal ^a   Ozyilmaz, Sinem ^a   Diker, Vesile ^a   Gul, Mehmet ^a  

^a Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Researh Hospital   (Turkey)

^b ACIBADEM UNIVERSITY   (Turkey)

^c Rize Devlet Hastanesi   (Turkey)

Author keywords

coronary atherosclerosis; diabetes mellitus; galectin 3

Indexed keywords

C REACTIVE PROTEIN; CREATININE; GALECTIN 3; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IOMEPROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GALECTIN-3, HUMAN;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; FAMILY HISTORY; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEUTROPHIL COUNT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SMOKING; SMOKING HABIT; TELEPHONE INTERVIEW; ATHEROSCLEROTIC PLAQUE; BLOOD; BLOOD VESSEL CALCIFICATION; COMPLICATION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; PROCEDURES; PROGNOSIS; RADIOGRAPHY; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TURKEY; UPREGULATION;

BIOMARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GALECTIN 3; HUMANS; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; TURKEY; UP-REGULATION; VASCULAR CALCIFICATION;

EID: 84936949646     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0000000000000252     Document Type: Article

References (27)

1. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364:829-841.
2. Bauer M, Caviezel S, Teynor A, Erbel R, Mahabadi AA, Schmidt-Trucksäss A. Carotid intima-media thickness as a biomarker of subclinical atherosclerosis. Swiss Med Wkly 2012; 142:w13705.
3. Desai CS, Ning H, Kang J, Folsom AR, Polak JF, Sibley CT, et al. Competing cardiovascular outcomes associated with subclinical atherosclerosis (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol 2013; 111:1541-1546.
4. Hassan A, Nazir SA, Alkadhi H. Technical challenges of coronary CT angiography: today and tomorrow. Eur J Radiol 2011; 79:161-171.
5. Soon K, Wong C. Coronary computed tomography angiography: a new wave of cardiac imaging. Intern Med J 2012; 42 (Suppl 5):22-29.
6. de Boer RA, Edelmann F, Cohen-Solal A, Mamas MA, Maisel A, Pieske B. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 2013; 15:1095-1101.
7. Pugliese G, Iacobini C, Ricci C, Blasetti Fantauzzi C, Menini S. Galectin-3 in diabetic patients. Clin Chem Lab Med 2014; 52:1413-1423.
8. Canning P, Glenn JV, Hsu DK, Liu FT, Gardiner TA, Stitt AW. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res 2007; 2007:51837.
9. Iacobini C, Amadio L, Oddi G, Ricci C, Barsotti P, Missori S, et al. Role of galectin-3 in diabetic nephropathy. J Am Soc Nephrol 2003; 14 (Suppl 3):264-270.
10. Jin QH, Lou YF, Li TL, Chen HH, Liu Q, He XJ. Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus. Chin Med J (Engl) 2013; 126:2109-2115.
11. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
12. Introduction: the American Diabetes Association's (ADA) evidence-based practice guidelines, standards, and related recommendations and documents for diabetes care. Diabetes Care 2012; 35 (Suppl 1):S1-S2.
13. European Association for Cardiovascular Prevention and Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32:1769-1818.
14. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51 (Suppl):5-40.
15. Leber AW, Becker A, Knez A, von Ziegler F, Sirol M, Nikolaou K, et al. Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J Am Coll Cardiol 2006; 47:672-677.
16. Rubinstein N, Ilarregui JM, Toscano MA, Rabinovich GA. The role of galectins in the initiation, amplification and resolution of the inflammatory response. Tissue Antigens 2004; 64:1-12.
17. Hashmi S, Al-Salam S. Galectin-3 is expressed in the myocardium very early post-myocardial infarction. Cardiovasc Pathol 2014. [Epub ahead of print].
18. McCullough PA. Practical experience using galectin-3 in heart failure. Clin Chem Lab Med 2014; 52:1425-1431.
19. Meijers WC, Januzzi JL, deFilippi C, Adourian AS, Shah SJ, van Veldhuisen DJ, de Boer RA. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J 2014; 167:853-860.
20. Bozcali E, Polat V, Aciksari G, Opan S, Bayrak IH, Paker N, Karakaya O. Serum concentrations of galectin-3 in patients with cardiac syndrome X. Atherosclerosis 2014; 237:259-263.
21. MacKinnon AC, Liu X, Hadoke PW, Miller MR, Newby DE, Sethi T. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology 2013; 23:654-663.
22. Nachtigal M, Ghaffar A, Mayer EP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol 2008; 172:247-255.
23. Iacobini C, Menini S, Ricci C, Scipioni A, Sansoni V, Cordone S, et al. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vasc Biol 2009; 29:831-836.
24. Madrigal-Matute J, Lindholt JS, Fernandez-Garcia CE, Benito-Martin A, Burillo E, Zalba G, et al. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc 2014; 3:pii: e000785.
25. Tunõn J, Blanco-Colio L, Cristébal C, Tarín N, Higueras J, Huelmos A, et al. Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease. Am J Cardiol 2014; 113:434-440.
26. Maiolino G, Rossitto G, Pedon L, Cesari M, Frigo AC, Azzolini M, et al. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2015; 35:725-732.
27. Menini S, Iacobini C, Ricci C, Blasetti Fantauzzi C, Salvi L, Pesce CM, et al. The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc Res 2013; 100:472-480.